Bacteriophage therapy and application of phages as biocontrol in plant production and 14 food processing, all necessitates acquisition of suitable phages. Depending on purpose, the selection 15 criteria of phage characteristics include lifestyle (lytic/lysogenic), host range, physical stability and 16 absence of unwanted genetic traits such as integrases, antibiotic resistance or bacterial virulence 17 factors. The exclusivity of antibiotic resistant clinical infections and possible development of phage-18 resistance instigates a need to continually build sizeable phage libraries and also be able to rapidly 19 isolate and characterise novel phages of specified bacterial hosts. Current methods for phage 20 isolation are both laborious and time consuming, suitable only for the isolation of a limited number 21 of phages. Thus, we developed the High-Throughput Screening (HITS) method for phages for fast 22 isolation and identification of potentially hundreds of distinct phages against single hosts. This 23 scalable method enables screening of hundreds of samples, in multiple simultaneous setups with 24 varying parameters increasing the likelihood of isolating multiple distinct phages specific for the 25 given conditions. The efficiency of the method is emphasised by our screening of 200 environmental 26 samples, resulting in the identification of an abundance of unique phage species lytic to Escherichia 27 coli, Salmonella Enterica, Enterococcus faecalis and Pseudomonas aeruginosa. 28 29 coli, Salmonella Enterica, Enterococcus faecalis; Pseudomonas aeruginosa.
31Pathogenic bacterial infections are becoming ever more difficult to treat, and even last resort 34 antibiotics such as the glycopeptide antibiotics vancomycin and teicoplanin are falling short as 35 efficient antimicrobial agents [2]. Bacteria are consecutively acquiring antibiotic resistance and 36 develop multidrug resistance [3], which necessitates the development of alternative antimicrobials 37 or means to increase the efficiency of existing antibiotics. Phage therapy (PT) is the therapeutic use 38 of the viral antagonists of bacteria, the bacteriophages (phages), to treat bacterial infections in humans 39 or animals. Most bacteriophages have narrow host-ranges, limiting their infectivity to specific species 40 or even strains. Consequently, PT does not instigate drastic perturbations of natural microbiota like 41 traditional antibiotic treatments [4]. Though studies have been limited, PT has not been shown to Yet, a successful biocontrol or PT venture requires phages with different modes of action, and 50 lots of them. Infection-specific phages and prepared phage cocktails are rarely generalisable [12].
51Clinical infections can be unparalleled and call for de novo isolation or genetic engineering, as was the 52 recent case with a 15-year old patient with cystic fibrosis caused by Mycobacterium abscessus [6]. More 53 than 10 000 phages infecting Mycobacterium smegmatis were screened in addition to 100 environmental 54 samples, resulting in only three su...